10 › 10.6
10.6 Lung disease and sleep-disordered breathing
Pages 67–68 · open in PDF
Recommendations in this section
- Class IIbLevel CAdaptive servo-ventilation may be considered in patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep apnoea to improve sleep quality, health-related QoL and symptoms.
- Class IIILevel AAdaptive servo-ventilation is not recommended in patients with HFrEF and sleep-disordered breathing with predominant central sleep apnoea because of an increased risk of CV and all-cause death.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 67 · PDF
Recommendation Table 19 — Recommendations for iron deficiency in patients with heart failure (see Evidence Tables 87 and 88) Recommendations Intravenous iron supplementation is recommended in patients with symptomatic HFrEF and iron deficiency to alleviate HF
Intravenous iron supplementation should be considered in patients with symptomatic HFrEF and iron deficiency to reduce the risk of 872–874,879,881,885,886,888
HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life. a Class of recommendation. b Level of evidence.
10.5. Cancer In patients with cancer, HF may occur as a result of the interactions between cancer therapy, cancer itself, and/or patients’ CV backgrounds (risk factors and coexisting CVD). Current cancer treatments may cause HF through direct cardiotoxic effects, or indirectly, favouring the occurrence of pathological conditions predisposing to HF, such as volume overload from i.v. infusions and corticosteroids, myocarditis, myocardial ischaemia, systemic or pulmonary hypertension, thromboembolism, arrhythmias, or valve disease.6,889,890 The definition of symptomatic and asymptomatic cancer therapy-related cardiac dysfunction is reported in Supplementary data online, Table S21. Cancer drugs causing HF are reported in Supplementary data online, Table S22. In patients who develop symptomatic HF during cancer therapy, FMT is recommended, regardless of LVEF.6 Discontinuation vs continuation of cardiotoxic drugs should be discussed by a multidisciplinary team. Severity of cancer therapy-related cardiac dysfunction guides the decision.6,891 Initiation of FMT for HFrEF is recommended in patients with asymptomatic moderate-to-severe cancer therapy-related cardiac dysfunction and should be considered in asymptomatic patients with mild presentations. For details regarding CV toxicity risk assessment process, diagnostic work-up, follow-up procedures, and therapeutic management of cardiotoxicity, we refer to the 2022 ESC Guidelines on cardio-oncology.6
10.6. Lung disease and sleep-disordered breathing Chronic obstructive pulmonary disease is common among patients with HF.892–894 Due to the overlap in symptoms and signs, the differentiation between HF and COPD may be difficult.895 Chronic obstructive pulmonary disease significantly impacts on symptoms and QoL, has been associated with HF undertreatment, and negatively influences prognosis of HF.893,896 Treatment of HF is generally well tolerated in COPD. The use of cardioselective beta-blockers (bisoprolol, metoprolol succinate, or nebivolol) should be preferred. In patients with asthma,
symptoms and improve QoL.875–879
diagnosis and treatment of acute and chronic heart failure,5 and has been used in almost all recent trials assessing the effects of i.v. iron supplementation in patients with HF and ID. However, it has recently been recognized that in patients with HF this definition does not reliably identify patients with absolute or functional ID. The current definition of ID may include patients with TSATs (≥20%) and serum ferritin levels (20– 100 mg/L) in the normal range, who are probably not iron deficient, exhibit a better prognosis, and might not respond to i.v. iron therapy.870 Moreover, serum ferritin levels are highly sensitive to inflammation and oxidative stress. Thus, an alternative definition of ID—TSAT <20%—has been proposed, mainly based on evidence from explorative analyses and meta-analyses of RCTs. A TSAT <20% has higher sensitivity and specificity compared with the previous definition of ID and is associated with higher mortality rates, independently of HF phenotype.869–871 Moreover, some meta-analyses of large RCTs reported that lower TSAT values better identify patients that will respond favourably to i.v. iron supplementation.872–874 The Task Force supports the use of this most recent definition of ID in patients with HF and recognizes the need for new trials investigating the efficacy of i.v. iron supplementation in patients with HF and ID as defined by TSAT <20%. Several trials, including AFFIRM-AHF,496 CONFIRM-HF,875 FAIR-HF,876,877 EFFECT-HF,878 and IRONMAN879 (where ID was defined as either ferritin <100 ng/mL, or ferritin 100– 299 ng/mL with TSAT <20%), have demonstrated that iron supplementation with i.v. ferric carboxymaltose is safe and effective in improving symptoms and QoL in patients with HF and LVEF <40%–45%. Thus, i.v. iron supplementation is recommended in patients with symptomatic HFrEF and ID to alleviate HF symptoms and improve QoL. Data in patients with HFpEF are scarce.880 The prognostic benefit of i.v. iron supplementation in patients with HF has been investigated in several RCTs and meta-analyses (see Supplementary data online, Section S7. 2).496,872,873,879,881–886 Given the conflicting results of major RCTs, the position of the Task Force is that evidence regarding the benefits of i.v. iron supplementation on strong endpoints is not conclusive. This is primarily due to the use of the old definition of ID as an enrolment criterion in almost all trials, the heterogeneity of RCTs in terms of enrolled populations as well as of i.v. iron doses and timing of administration and that some major RCTs were affected by the coronavirus disease 2019 pandemic. Thus, i.v. iron supplementation with ferric carboxymaltose or ferric derisomaltose should be considered in patients with symptomatic HFrEF and ID to reduce the risk of HFH, taking into account that patients with TSAT <20% might benefit most. Further trials using TSAT <20%, or other criteria that do not rely on ferritin levels as inclusion criteria, are warranted. In patients with HFrEF and mild to moderate anaemia enrolled in the RED-HF trial,887 darbepoetin-alpha failed to reduce all-cause death or HFH and showed an increased risk of thromboembolic events. Thus, erythropoietin-stimulating agents should be avoided for the treatment of anaemia related to HF.
Page 68 · PDF
10.7. Anxiety, depression, and cognitive impairment
these medications require more caution and should be started at low doses after consideration of the risks and benefits, with close monitoring for signs of airway obstruction, and appropriate supervision.897 Chronic obstructive pulmonary disease exacerbations should not be a cause of beta-blocker discontinuation.898 Inhaled corticosteroids and beta-adrenergic agonists have not been specifically studied in patients with HF; however, they do not seem to increase CV risk.899,900 In addition, appropriate management of COPD can improve cardiac function.901 Sleep-disordered breathing is found in over one-third of patients with HF and is even more prevalent in DHF. Sleepdisordered breathing includes OSA, central sleep apnoea (CSA), and mixed disease. SDB negatively impacts disease progression and prognosis.902,903 Patients with a suspicion of SDB should be referred for overnight polysomnography to definitively diagnose SDB, and to document the predominant type of sleep apnoea (central vs obstructive).902 The therapeutic approach to SDB includes the correction of underlying causes, when identified. The use of adaptive servo-ventilation (ASV) in patients with HFrEF and predominantly CSA is not recommended, based on the results of the SERVE-HF trial,904 which showed an increase in both all-cause and CV death in patients with chronic HF, LVEF ≤45%, and SDB with predominant CSA.904 The ADVENT-HF trial randomized 731 patients with HF, LVEF ≤45%, and coexisting SDB, mostly OSA (73%) to standard optimal treatment alone or standard optimal treatment and ASV (1:1). Over a mean follow-up period of 3.6 years, ASV had a neutral effect on the primary composite outcome (the cumulative incidence of all-cause death, first CV hospitalization, new-onset AF/flutter, and delivery of an appropriate ICD shock).905 However, ASV improved sleep quality and structure, health-related QoL, and symptoms of patients with SDB.905 Thus, in patients with SDB and predominant OSA, nocturnal hypoxaemia can be treated with nocturnal oxygen supplementation, continuous positive airway pressure (CPAP), bilevel positive airway pressure, and ASV. When SDB is caused by CSA, implantable phrenic nerve stimulation was found to be safe and effective in reducing the apnoea–hypopnoea index in a small RCT.906–908
10.8. Frailty Frailty is defined as a multidimensional, dynamic, and potentially reversible state, related to, but independent of, age, that makes individuals more vulnerable to the effects of stressors and at increased risk of poor outcomes. A score assessing frailty including four domains (clinical, functional, psychocognitive, and social) has recently been proposed.918 The presence of frailty might have an impact on disease management and is associated with higher rates of death and hospitalizations, and reduced health-related QoL, regardless of which tool was used to assess frailty.919–923 In patients with HF, frailty is particularly prevalent in older adults. When frailty is suspected or identified, a multidisciplinary approach to facilitate an individualized management is warranted.918,922,924
Recommendation Table 20 — Recommendations for lung disease and sleep-disordered breathing (see Evidence Table 89) Recommendations
Anxiety and depression are common findings in patients affected by chronic and disabling conditions, such as HF, and need to be promptly identified to minimize psychological distress and its negative consequences.909 Depression affects 20% of patients with HF, and it may affect adherence to FMT. Its prevalence is higher in women, and it is associated with worse clinical status and poorer prognosis.910–912 The diagnosis of depression typically relies on standardized questionnaires and clinical interviews. Symptom overlap between HF and depression can complicate diagnosis, as both conditions may present with cognitive issues (e.g. difficulty concentrating) and physical symptoms (e.g. fatigue). Several validated questionnaires are available for screening clinically significant depressive symptoms911 (see Supplementary data online, Section S7.4, Table S23). Cognitive impairment in these patients has been reported.911,913 However, there is still no consensus on the best therapy for patients with HF and depression. Cognitive behavioural therapy has demonstrated significant favourable long-term (4–9 months) reduction of anxiety and depression and improvement in QoL compared with nontreated patients.914,915 The safety of sertraline and escitalopram has been demonstrated, although without a significant reduction in depression compared with placebo.916,917 Tricyclic antidepressants should be avoided for the treatment of depression in HF as they may cause hypotension, WHF, and arrhythmias.911,912
Adaptive servo-ventilation may be considered in
Recommendation Table 21 — Recommendations for anxiety, depression, and frailty (see Evidence Tables 90 and 91)
apnoea to improve sleep quality, health-related QoL and symptoms.905
Adaptive servo-ventilation is not recommended III
apnoea because of an increased risk of CV and all-cause death.
Assessment of anxiety, depression and frailty
CV, cardiovascular; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life. a Class of recommendation. b Level of evidence.
in patients with HFrEF and sleep-disordered breathing with predominant central sleep
should be considered in patients with HF to support the development of personalized care plans and to identify factors that may contribute to adverse outcomes.909,914,915,920,923 HF, heart failure. a Class of recommendation. b Level of evidence.
patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep